%0 Journal Article
%A Grosu, Anca-Ligia
%A Weber, Wolfgang A
%A Graf, Erika
%A Mix, Michael
%A Nestle, Ursula
%A Schimek-Jasch, Tanja
%A Wiehle, Rolf
%A Mader, Irina
%A Würtemberger, Urs
%A Langen, Karl-Josef
%A Niyazi, Maximilian
%A Paulsen, Frank
%A König, Liane
%A Giordano, Frank Anton
%A Spehl, Irina
%A Bernhardt, Denise
%A Schymalla, Markus M
%A Pöttgen, Christoph
%A Semrau, Sabine
%A Brunner, Thomas
%A Hültenschmidt, Beatrix
%A Krause, Bernd Joachim
%A Ciernik, Ilja Frank
%A Beck, Jürgen
%A Baumert, Brigitta G
%A Meyer, Philipp T
%A Urbach, Horst
%A Popp, Ilinca
%T O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial.
%J The lancet / Oncology
%V nn
%@ 1470-2045
%C London
%I The Lancet Publ. Group
%M DKFZ-2025-03035
%P nn
%D 2025
%Z epub
%X O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET has a higher specificity than contrast-enhanced T1-weighted MRI (CE-T1MRI) in diagnosing recurrent glioblastoma. We aimed to evaluate whether a FET-PET-based target volume delineation, compared with CE-T1MRI, improves outcomes in patients with recurrent glioblastoma scheduled for re-irradiation.GLIAA was a multicentre, open-label, parallel randomised study done in 15 radiation oncology centres in Germany. Patients aged 18 years or older with a Karnofsky performance score greater than 60
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41429128
%R 10.1016/S1470-2045(25)00642-4
%U https://inrepo02.dkfz.de/record/307436